Federal Register notice: FDA announces a 10/6 advisory committee meeting to discuss a Veru Inc. request for an emergency use authorization for tubulin...
Federal Register notice: FDA announces that a product was approved using a priority review voucher Genentechs Vabysmo (faricimab-svoa).
CDER and CBER accept the first letter of intent submission for the new Innovative Science and Technology Approaches for New Drugs pilot program to dev...
After reporting new clinical trial data, Ionis Pharmaceuticals and AstraZeneca plan to submit an NDA for eplontersen for treating patients with heredi...
Four drug industry stakeholders ask FDA to clarify elements in a draft guidance on interoperable exchange of information under the Drug Supply Chain S...
Pacira BioSciences plans to submit a supplemental NDA early next year to broaden the label on its post-surgical pain drug Exparel (bupivacaine extende...
CBER announces a 10/5 Webinar entitled Study Data Standards Update for CBER: Your Guide to a Successful Submission.
FDA lifts its clinical hold on Sareptas investigational Duchenne muscular dystrophy drug SRP-5051.
